Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CBIO with free AI briefings, catalyst countdowns, and dilution alerts.

CBIO · CRESCENT BIOPHARMA, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$289.4M Cash on Hand
37.4mo Cash Runway
Follow CBIO by email Get an email when CBIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CBIO, unsubscribe in one click. Privacy

📣 What CBIO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001 Locally Advanced / Metastatic Solid Tumors Phase 1/2 · NCT07335497 Recruiting
CR-002 Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic… Phase 1/2 · NCT07909031 Recruiting
FOLFOX Locally Advanced / Metastatic Solid Tumors Phase 1/2 · NCT07335497 Recruiting
Gemcitabin Locally Advanced / Metastatic Solid Tumors Phase 1/2 · NCT07335497 Recruiting

Also used in these trials (approved or third-party drugs, not CBIO's own candidates): Capecitabine, Carboplatin, Cisplatin, Oxaliplatin, Paclitaxel, Pemetrexed Disodium, Trifluridine And Tipiracil.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CBIO holds $289.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $23.2M/quarter from operations, an estimated runway of 37.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CBIO files for a raise →

👥 Who Owns CBIO

Insiders 10.7% Other 5%+ holders 27% Institutions (135 holders) 62.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
Peter Harwin 5%+ holder (13D) 6,602,408 16.97% 2026-07-16
FMR LLC Institution (13G, 5%+) 4,133,514 10.63% 2025-12-31
BVF PARTNERS L P/IL Institution (13G, 5%+) 3,691,518 9.49% 2026-09-30
Fairmount Funds Management LLC
Director, 10% owner · +2.31M options
Insider 3,601,316 9.26% 2026-07-16
Vestal Point Capital, LP Institution (13G, 5%+) 3,000,000 7.71% 2026-09-30
Venrock Healthcare Capital Partners III, 5%+ holder (13G) 2,228,641 5.73% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 2,075,291 5.34% 2026-09-30
ForGrowth III PA B.V. 5%+ holder (13G) 1,677,852 4.31% 2025-12-08
Joshua T Brumm
Chief Executive Officer, Director · +526,139 options
Insider 271,765 0.70% 2026-09-16
Jonathan McNeill
President and COO · +250,865 options
Insider 134,588 0.35% 2026-09-16
Christopher Grant Doughty
Chief Business Officer · +58,855 options
Insider 62,194 0.16% 2025-12-15
Jan Pinkas
Chief Scientific Officer · +212,499 options
Insider 21,581 0.06% 2026-09-16

Share count 38,895,442 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CBIO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CBIO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.